Livzon Pharmaceutical Group Inc - Class H

HKSE:01513 (China)   Class H
HK$ 27.20 (+1.68%) Jun 4
11.75
P/B:
2.52
Market Cap:
HK$ 35.24B ($ 4.51B)
Enterprise V:
HK$ 26.23B ($ 3.36B)
Volume:
431.10K
Avg Vol (2M):
768.77K
Also Trade In:
Volume:
431.10K
Avg Vol (2M):
768.77K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Livzon Pharmaceutical Group Inc ( ) from 2014 to Jun 04 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Livzon Pharmaceutical Group stock (HKSE:01513) PE ratio as of Jun 04 2024 is 11.75. More Details

Livzon Pharmaceutical Group Inc (HKSE:01513) PE Ratio (TTM) Chart

To

Livzon Pharmaceutical Group Inc (HKSE:01513) PE Ratio (TTM) Historical Data

Total 1220
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Livzon Pharmaceutical Group PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-04 11.8 2024-03-26 11.7
2024-06-03 11.6 2024-03-25 11.9
2024-05-31 11.4 2024-03-22 11.8
2024-05-30 11.5 2024-03-21 12.0
2024-05-29 11.6 2024-03-20 11.9
2024-05-28 11.8 2024-03-19 11.9
2024-05-27 11.9 2024-03-18 11.9
2024-05-24 11.7 2024-03-15 11.9
2024-05-23 11.7 2024-03-14 11.9
2024-05-22 11.8 2024-03-13 12.1
2024-05-21 11.8 2024-03-12 12.4
2024-05-20 12.3 2024-03-11 12.2
2024-05-17 12.2 2024-03-08 12.1
2024-05-16 12.5 2024-03-07 12.1
2024-05-14 12.8 2024-03-06 12.3
2024-05-13 12.8 2024-03-05 12.4
2024-05-10 12.7 2024-03-04 12.5
2024-05-09 12.1 2024-03-01 12.1
2024-05-08 12.0 2024-02-29 11.8
2024-05-07 12.0 2024-02-28 11.8
2024-05-06 11.9 2024-02-27 11.8
2024-05-03 11.8 2024-02-26 11.6
2024-05-02 11.8 2024-02-23 11.8
2024-04-30 11.6 2024-02-22 11.9
2024-04-29 11.3 2024-02-21 11.5
2024-04-26 11.3 2024-02-20 11.5
2024-04-25 11.4 2024-02-19 11.2
2024-04-24 11.2 2024-02-16 11.2
2024-04-23 11.1 2024-02-15 10.8
2024-04-22 11.1 2024-02-14 10.9
2024-04-19 11.0 2024-02-09 10.8
2024-04-18 11.2 2024-02-08 11.0
2024-04-17 11.0 2024-02-07 11.0
2024-04-16 11.1 2024-02-06 11.2
2024-04-15 11.0 2024-02-05 10.3
2024-04-12 10.9 2024-02-02 10.2
2024-04-11 10.9 2024-02-01 10.2
2024-04-10 10.9 2024-01-31 10.3
2024-04-09 11.0 2024-01-30 10.4
2024-04-08 10.8 2024-01-29 10.5
2024-04-05 10.6 2024-01-26 10.5
2024-04-03 10.8 2024-01-25 10.6
2024-04-02 10.9 2024-01-24 10.3
2024-03-28 11.5 2024-01-23 10.2
2024-03-27 11.6 2024-01-22 10.0

Livzon Pharmaceutical Group Inc (HKSE:01513) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment in PRC which is pharmaceutical manufacturing.